【Major Developments】 Global Medical (02666) plans to invest RMB15.03 million to establish a joint venture, creating a collaborative platform integrating policy alignment, technology transfer, and clinical validation. Fosun Pharma (02196) announced that its subsidiary's drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder has been accepted by the NMPA. Sino Biopharm (01177) received NMPA approval for the clinical trial application of LM-350 "CDH17 ADC." Acotec Scientific-B (06669) obtained approval from China's NMPA for the registration of its coronary artery exchangeable balloon dilation catheter, Jingyi®. Beauty Farm Medical & Health (02373) subsidiary intends to acquire Nareal’s medical and aesthetic assets for RMB40 million, adding 19 directly operated stores. China Isotope & Radiation (01763) exported its self-produced irradiation equipment to the Latin American market for the first time.

【Operational Performance】 Trip.com Group-S (09961) reported Q3 net profit attributable to shareholders of RMB19.89 billion, up 194.01% YoY. H&H International (01112) posted a 12.0% YoY increase in total revenue for the first nine months. Weibo-SW (09898) disclosed a Q1-Q3 net profit attributable to shareholders of $454 million, rising 55.43% YoY. Baidu Group-SW (09888) recorded Q3 total revenue of RMB31.2 billion, with AI-driven new business revenue surging over 50% YoY. XIAOMI-W (01810) achieved a historic high adjusted net profit of RMB11.311 billion in Q3, while smartphone shipments grew YoY for the ninth consecutive quarter. China Oriental Group (00581) sold approximately 2.1 million tons of self-produced steel products in Q3. Kanzhun Ltd-W (02076) reported Q3 adjusted net profit of ~RMB992 million, up 34.2% YoY.